Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Robot-Assisted microsurgery: a new frontier for tissue repair and lymphedema

NCT ID NCT06866197

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a robotic system called Symani to help surgeons perform delicate microsurgery for two types of procedures: free tissue transfer (moving tissue from one part of the body to another) and lymphatic surgery (to treat lymphedema, a condition causing swelling). About 180 adults will take part, and researchers will check if the robot works safely and effectively by looking at how well the tiny blood vessels stay open after surgery and whether any serious problems occur. Participants will follow standard care and may need to fill out questionnaires or have limb measurements taken.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults, according to the local law * Patient agrees to participate in the study, return for all required follow-up visits, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure * Patient with a clinical indication for a microsurgical anastomosis for a free flap transfer surgery and/or lymphatic surgery Investigator considers candidate acceptable for free flap transfer surgery and/or lymphatic surgery with a robotic assisted microsurgical anastomosis in accordance with the Symani System IFU Inclusion Criteria for Therapeutic Lymphatic Patients: * For lymphedema of the extremities, swelling of lymphedema that is not completely reversed by decongestion therapy modalities. (Not applicable for patients with lymphedema of the head and neck) * For lymphedema of the extremities, at least one of the following positive quantitative measurements (not applicable for patients with lymphedema of the head and neck): 1. Volumetry differential between diseased limb and contralateral limb must be at least 10% of the other 2. Bioimpedance (L-Dex) differential, if feasible, between diseased limb and contralateral limb of at least 10 units * Maintain complete decongestive therapy (CDT), according to International Society of Lymphology (ISL) guidelines, for a minimum duration of four (4) weeks prior to screening * Willingness to comply with recommended regimen of self-care, with consistent use of compression garments from screening through the entire study duration * Patient must be diagnosed with Lymphedema * Patient must have a body mass index (BMI) of ≤ 35 Inclusion Criteria for Prophylactic Lymphatic Patients: * The patient has at least one identifiable risk factor for developing lymphedema of the extremities * Patient with a body mass index (BMI) of ≤ 35 Exclusion Criteria: * Patients who are not capable and/or unwilling to provide informed consent * Clinically significant cardiovascular, digestive, respiratory, endocrine, liver or central nervous system disorders, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigators discretion. * Known history of significant bleeding, coagulopathy, or Von Willebrand's disease * Patients with implanted pacemaker * Planned vein graft (either venous or arterial) * Previously documented history of chronic kidney disease (eGFR ≤ 30) * Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or outcomes * Patients belonging to vulnerable populations, such as pregnant women, or patients ineligible to participate for other reasons in the judgement of the investigator Exclusion Criteria for Free Tissue Transfer Patients: * Patients with buried flaps * Multiple flaps planned for the procedure Exclusion Criteria for Therapeutic Lymphatic Patients: * Patients with venous edema (arising from increased capillary filtration) * Patients with other medical conditions that could lead to acute limb edema, such as (but not limited to) acute venous thrombosis or heart failure * Current infection in the affected area of lymphedema * Current evidence of malignancy * Known iodine sensitivity * Patient's lymphatic disease is due to lipedema * Patients with bilateral lymphedema or lymphedema in multiple anatomical locations Exclusion Criteria for Prophylactic Lymphatic Participants: * Patients for whom prophylactic surgery on more than one limb is planned * Known iodine sensitivity * Patients with post-thrombotic syndrome, arterial insufficiency, deep vein thrombosis or any other medical condition that could make them ineligible to participate in the judgment of the investigator * Patients diagnosed with lymphedema Intraoperative Exclusion Criteria: * Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest * The patient does not have at least two robotic sutures attempted during the index procedure

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Free tissue transfer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Saint Vincent's Hospital Melbourne

    RECRUITING

    Melbourne, Victoria, 3065, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.